Eptifibatide and Cirrhosis: Rethinking GPIIb-IIIa Inhibitors for Acute Coronary Syndrome in the Setting of Liver Dysfunction.

Content Provider	Europe PMC
Author	Weinreich, Michael Mendoza, Dexter Pettei, Thomas Grayver, Evelina
Copyright Year	2014
Abstract	Glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors, such as eptifibatide, are routinely used in the setting of acute coronary syndrome (ACS) prior to or during percutaneous coronary intervention (PCI). While numerous studies have demonstrated improved clinical outcomes with eptifibatide use, adverse effects including thrombocytopenia have also been noted. For this reason, patients with baseline thrombocytopenia or liver disease should be cautiously evaluated prior to drug administration. Here we report a case of acute profound and prolonged eptifibatide-induced thrombocytopenia in a patient with cirrhotic liver dysfunction. We propose and discuss the need for a risk stratification tool to be established for identifying which patients with ACS in the setting of chronic liver disease receive GPIIb/IIIa inhibitors.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC5358269&blobtype=pdf
ISSN	19232829
Journal	Cardiology Research [Cardiol Res]
Volume Number	5
DOI	10.14740/cr357w
PubMed Central reference number	PMC5358269
Issue Number	6
PubMed reference number	28352453
e-ISSN	19232837
Language	English
Publisher	Elmer Press
Publisher Date	2014-12-04
Access Restriction	Open
Rights License	This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright 2014, Weinreich et al.
Subject Keyword	GPIIb/IIIa inhibitors Integrilin Acute coronary syndrome Thrombocytopenia Cirrhosis Chronic liver disease
Content Type	Text
Resource Type	Article
Subject	Cardiology and Cardiovascular Medicine